Correction to: Scientific Reports https://doi.org/10.1038/s41598-025-14572-1, published online 11 August 2025
The original version of this Article contained errors in Figure 2, where panels (a) and (b) were inadvertently omitted during production. The original Figure 2 and accompanying legend appear below.
Expression of SF-25 Ag in ATL, HTLV-1 carriers and healthy controls. (a) Representative data of SF-25 Ag and CD4 expression with smoldering ATL. SF-25-expressing cells also expressed CD4. (b) KUT-1 and MT-1 cells were incubated for 30 min at 4 °C with 1 µg/mL of FITC-conjugated murine SF-25 Mab (FITC-m-SF-25 Mab) or FITC-conjugated irrelevant murine IgG1 Mab (FITC-m-IgG1), washed with PBS, and analyzed by flow cytometry. (c) Patients with ATL and healthy controls were categorized as follows: Group A, the healthy controls without HTLV-1 infection; Group B, the healthy HTLV-1 carriers; Group C, the patients with smoldering ATL; Group D, the patients with chronic ATL; and Group E, the patients with acute ATL. Notably, the expression of SF-25 in ATL patients was significantly higher than that in both HTLV-1 healthy carriers and healthy controls without HTLV-1 infection (P < 0.001). ATL adult T-cell leukemia/lymphoma; FITC fluorescein isothiocyanate; HTLV-1, human T-lymphotropic virus 1.
The original Article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Suzuki, S., Lin, XY., Hanada, S. et al. Correction: Chimeric SF-25 monoclonal antibody as a targeted therapy for SLC3A2 in adult T-cell leukemia/lymphoma. Sci Rep 15, 34304 (2025). https://doi.org/10.1038/s41598-025-21843-4
Published:
DOI: https://doi.org/10.1038/s41598-025-21843-4
